Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Research Coverage Started at Sanford C. Bernstein
Sanford C. Bernstein initiated coverage on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report sent to investors on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $99.00 target price on the biopharmaceutical company’s stock.
ALNY has been the subject of a number of other research reports. Credit Suisse Group restated a hold rating and set a $50.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 9th. Chardan Capital set a $110.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, June 12th. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 13th. Ladenburg Thalmann Financial Services set a $90.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, July 17th. Finally, J P Morgan Chase & Co restated a hold rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $79.79.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 82.63 on Thursday. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $86.92. The stock’s market cap is $7.12 billion. The company’s 50 day moving average is $79.93 and its 200 day moving average is $59.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. The business had revenue of $19 million for the quarter, compared to analyst estimates of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm’s revenue for the quarter was up 160.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.21) EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals will post ($5.21) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-nasdaqalny-research-coverage-started-at-sanford-c-bernstein/1463567.html.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total transaction of $825,000.00. Following the completion of the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sanofi bought 297,501 shares of the company’s stock in a transaction on Wednesday, May 31st. The shares were acquired at an average price of $71.87 per share, with a total value of $21,381,396.87. The disclosure for this purchase can be found here. Insiders have sold a total of 64,125 shares of company stock valued at $4,325,000 over the last 90 days. 4.30% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Comerica Bank boosted its stake in Alnylam Pharmaceuticals by 20.0% in the fourth quarter. Comerica Bank now owns 16,269 shares of the biopharmaceutical company’s stock valued at $677,000 after buying an additional 2,712 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares in the last quarter. AQR Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $1,036,000. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $24,885,000. Finally, UBS Asset Management Americas Inc. boosted its stake in Alnylam Pharmaceuticals by 9.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,667,426 shares of the biopharmaceutical company’s stock valued at $62,429,000 after buying an additional 148,664 shares in the last quarter. Hedge funds and other institutional investors own 88.93% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.